Stock RVMD REVOLUTION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
39.18 USD +0.93% Intraday chart for Revolution Medicines, Inc. +10.09% +36.61%
04-12 Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating MT
04-12 Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
AQ
Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating
MT
Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating
MT
North American Morning Briefing : Stock Futures -2-
DJ
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
AQ
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
AQ
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs
AQ
Revolution Medicines to Participate in Upcoming Investor Conferences
AQ
Aethon Therapeutics, Inc. Announces Collaboration with Revolution Medicines, Inc. to Discover and Develop Novel Aethon Antibody Programs
CI
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
AQ
Revolution Medicines Insider Sold Shares Worth $805,652, According to a Recent SEC Filing
MT
Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target
MT
HC Wainwright Raises Revolution Medicines Price Target to $44 From $28, Maintains Buy Rating
MT
Revolution Medicines Files Mixed-Securities Shelf
MT
Wedbush Adjusts Revolution Medicines' Price Target to $42 From $41, Keeps Outperform Rating
MT
Revolution Medicines Q4 Net Loss Widens, Revenue Drops
MT
Transcript : Revolution Medicines, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Revolution Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (RVMD) REVOLUTION MEDICINES Posts Q4 Revenue $742,000, vs. Street Est of $1.2M
MT
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVMD Stock
  4. News Revolution Medicines, Inc.